These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38490372)

  • 1. No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.
    Lee BR; Brostek AR; Kaffenberger BH
    J Am Acad Dermatol; 2024 Jul; 91(1):100-102. PubMed ID: 38490372
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologic drugs during COVID-19 outbreak.
    Montesu MA; Biondi G; Sotgiu G; Sucato F; Satta R
    Int J Dermatol; 2020 Oct; 59(10):1293. PubMed ID: 32767379
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.
    Molinelli E; Diotallevi F; Simonetti O; Brisigotti V; Sapigni C; Radi G; Campanati A; Offidani A
    Dermatol Ther; 2020 Nov; 33(6):e14256. PubMed ID: 32860474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
    Patsatsi A; Kyriakou A
    Clin Dermatol; 2021; 39(1):52-55. PubMed ID: 33972053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
    Rosi E; Pimpinelli N; Prignano F
    J Dermatolog Treat; 2022 Feb; 33(1):599. PubMed ID: 32432955
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-COVID-19 measurements for hidradenitis suppurativa patients.
    Giamarellos-Bourboulis EJ; Bettoli V; Jemec GBE; Del Marmol V; Marzano AV; Prens EP; Tzellos T; Zouboulis CC
    Exp Dermatol; 2021 Jun; 30 Suppl 1(Suppl 1):18-22. PubMed ID: 34085330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina].
    Zimman S; Cura MJ; Luna PC; Echeverría CM; Mazzuoccolo LD
    Actas Dermosifiliogr (Engl Ed); 2020 Nov; 111(9):806-807. PubMed ID: 32576376
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 in patients with hidradenitis suppurativa.
    Lima XT; Cueva MA; Alora MB
    Br J Dermatol; 2021 Jan; 184(1):182-184. PubMed ID: 32880904
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa.
    Iannone M; Janowska A; Tonini G; Davini G; Dini V
    Clin Dermatol; 2021; 39(4):701-702. PubMed ID: 34809775
    [No Abstract]   [Full Text] [Related]  

  • 10. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
    Yim RM; Singh I; Armstrong AW
    Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
    Yen CF; Huang YH; Chi CC
    Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
    Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
    [No Abstract]   [Full Text] [Related]  

  • 13. Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation.
    Kozera EK; Porter M; Paek SY; Mintoff D; McMeniman E; Oon HH; Chandran NS; Glasenhardt K; Ring HC; Frew JW
    Dermatology; 2024; 240(3):494-506. PubMed ID: 37963431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic.
    Montero-Vilchez T; Martinez-Lopez A; Salvador-Rodriguez L; Molina-Leyva A; Arias-Santiago S
    Dermatol Ther; 2020 Nov; 33(6):e13875. PubMed ID: 32558071
    [No Abstract]   [Full Text] [Related]  

  • 15. Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.
    Tampouratzi E; Kanni T; Katsantonis J; Douvali T
    F1000Res; 2019; 8():2002. PubMed ID: 33456757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa'.
    Martora F; Marasca C; Battista T; Fabbrocini G; Ruggiero A
    Clin Exp Dermatol; 2022 Nov; 47(11):2026-2028. PubMed ID: 35727206
    [No Abstract]   [Full Text] [Related]  

  • 17. One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
    Lanna C; Mazzilli S; Zangrilli A; Bianchi L; Campione E
    Dermatol Ther; 2019 Nov; 32(6):e13089. PubMed ID: 31577864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.
    Kearns DG; Chat VS; Uppal S; Wu JJ
    J Am Acad Dermatol; 2020 Dec; 83(6):e433-e434. PubMed ID: 32735966
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.
    Blaszczak A; Trinidad JCL; Cartron AM
    J Am Acad Dermatol; 2020 Jul; 83(1):e31. PubMed ID: 32283230
    [No Abstract]   [Full Text] [Related]  

  • 20. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.